Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.

Abstract

AIMS:

We investigated the effects of the SGLT2 inhibitor luseogliflozin on blood and urinary glucose and body weight.

METHODS:

Luseogliflozin 2.5 mg was administered once daily for 24 weeks to 30 outpatients with type 2 diabetes. Urinary glucose concentration, continuous glucose monitoring values, HbA1c, fasting glucose, and body weight were evaluated. Correlations with urinary glucose, subcutaneous/visceral fat mass, insulin, EPA/AA ratio, plasma free fatty acids, ghrelin, blood ketones, plasma 1,5-anhydro-D-glucitol were evaluated.

RESULTS:

Urinary glucose significantly increased from 11.1 ± 11.8 g at Week -4 to 84.5 ± 46.8 g at Week 24. HbA1c significantly declined from 7.88 ± 0.88% to 7.36 ± 1.13% at Week 24. Mean blood glucose significantly decreased from 149.6 ± 41.8 to 131.6 ± 31.1 mg/dL at Week 24. Subcutaneous and visceral fat mass was also significantly decreased, as were AST and ALT (P < 0.01). Blood urea nitrogen was significantly increased, and urate significantly decreased from 5.04 ± 1.07 to 4.53 ± 0.94 mg/dL. The homeostasis model assessment ratio remained significantly improved throughout the treatment period. Acyl ghrelin levels remained constant but des-acyl ghrelin increased significantly.

CONCLUSIONS:

Luseogliflozin monotherapy resulted in an improvement in blood glucose, a decrease in body weight, and decreased insulin resistance. Luseogliflozin appears to be an effective therapy for obese diabetics.

• Authors: Hideaki Jinnouchi, Akira Yoshida, Hiromi Tsuyuno, Kiyoko Iwamoto, Seigo Sugiyama, Kunio Hieshima, Keizo Kajiwara, Noboru Kurinami, Tomoko Suzuki, Katsunori Jinnouchi, Tomio Jinnouchi
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 182 Pg. 108916 (Dec 2021) ISSN: 1872-8227 [Electronic] Ireland
• PMID: 34119556 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Blood Glucose
• Sodium-Glucose Transporter 2 Inhibitors
• Sorbitol
• 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol
• Glucose

Topics

• Blood Glucose
• Blood Glucose Self-Monitoring
• Body Weight
• Diabetes Mellitus, Type 2 (drug therapy)
• Glucose
• Humans
• Sodium-Glucose Transporter 2 Inhibitors
• Sorbitol (analogs & derivatives)